Maxim Group Remains a Buy on VolitionRX (VNRX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on VolitionRX (VNRXResearch Report) yesterday and set a price target of $5.00. The company’s shares opened today at $1.98.

According to TipRanks, McCarthy is an analyst with an average return of -37.8% and a 14.69% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Daré Bioscience, and SELLAS Life Sciences Group.

Currently, the analyst consensus on VolitionRX is a Moderate Buy with an average price target of $5.00.

See today’s best-performing stocks on TipRanks >>

Based on VolitionRX’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $32.71 thousand and a GAAP net loss of $7.74 million. In comparison, last year the company earned a revenue of $25.48 thousand and had a GAAP net loss of $7.14 million

Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VNRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Austin, TX.

Read More on VNRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More